Exclusive European data from BIO-Europe’s inaugural C-suite survey, shared with European Biotechnology, shows a sector expecting better funding conditions while struggling with investor caution. Among 69 executives at European-headquartered companies, 84% identify investor risk aversion as biotech investment’s biggest constraint, even as 70% expect their company’s access to capital to improve over the next year.Read More
Report: Europe’s biotech leaders see recovery, but investors remain the obstacle
